DB:HPX

Stock Analysis Report

Executive Summary

Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals.

Snowflake

Fundamentals

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Hisamitsu Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

HPX

0.8%

DE Pharmaceuticals

1.4%

DE Market


1 Year Return

-22.4%

HPX

-4.8%

DE Pharmaceuticals

3.7%

DE Market

Return vs Industry: HPX underperformed the German Pharmaceuticals industry which returned -4.8% over the past year.

Return vs Market: HPX underperformed the German Market which returned 3.7% over the past year.


Shareholder returns

HPXIndustryMarket
7 Day3.6%0.8%1.4%
30 Day4.4%0.2%1.3%
90 Day17.7%10.4%3.4%
1 Year-21.0%-22.4%-1.6%-4.8%7.0%3.7%
3 Year-4.1%-8.2%-5.3%-13.2%18.5%8.3%
5 Year71.4%58.1%-3.0%-14.9%42.2%22.9%

Price Volatility Vs. Market

How volatile is Hisamitsu Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hisamitsu Pharmaceutical undervalued compared to its fair value and its price relative to the market?

28.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: HPX (€40.6) is trading below our estimate of fair value (€57.13)

Significantly Undervalued: HPX is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: HPX is good value based on its PE Ratio (23.8x) compared to the Pharmaceuticals industry average (31.7x).

PE vs Market: HPX is poor value based on its PE Ratio (23.8x) compared to the German market (19.3x).


Price to Earnings Growth Ratio

Low PEG Ratio: HPX is poor value based on its PEG Ratio (2.7x)


Price to Book Ratio

PB vs Industry: HPX is good value based on its PB Ratio (1.7x) compared to the DE Pharmaceuticals industry average (2.6x).


Next Steps

Future Growth

How is Hisamitsu Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

8.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HPX's forecast earnings growth (8.8% per year) is above the savings rate (0.2%).

Earnings vs Market: HPX's earnings (8.8% per year) are forecast to grow slower than the German market (12.7% per year).

High Growth Earnings: HPX's earnings are forecast to grow, but not significantly.

Revenue vs Market: HPX's revenue (3.4% per year) is forecast to grow slower than the German market (5% per year).

High Growth Revenue: HPX's revenue (3.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: HPX's Return on Equity is forecast to be low in 3 years time (7.8%).


Next Steps

Past Performance

How has Hisamitsu Pharmaceutical performed over the past 5 years?

0.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HPX's earnings have grown by 0.3% per year over the past 5 years.

Accelerating Growth: HPX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HPX had negative earnings growth (-6.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.4%).


Return on Equity

High ROE: HPX's Return on Equity (7.3%) is considered low.


Return on Assets

ROA vs Industry: HPX's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: HPX's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Hisamitsu Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: HPX's short term assets (¥200.3B) exceeds its short term liabilities (¥36.7B)

Long Term Liabilities: HPX's short term assets (200.3B) exceeds its long term liabilities (15.2B)


Debt to Equity History and Analysis

Debt Level: HPX's debt to equity ratio (0.6%) is considered satisfactory

Reducing Debt: HPX's debt to equity ratio has reduced from 1.1% to 0.6% over the past 5 years.

Debt Coverage: HPX's debt is well covered by operating cash flow (1036.9%).

Interest Coverage: HPX earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: HPX has a low level of unsold assets or inventory.

Debt Coverage by Assets: HPX's debt is covered by short term assets (assets are 125.907600x debt).


Next Steps

Dividend

What is Hisamitsu Pharmaceutical's current dividend yield, its reliability and sustainability?

1.65%

Current Dividend Yield


Upcoming Dividend Payment

Purchase Hisamitsu Pharmaceutical before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield vs Market

company1.6%marketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Years1.7%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: HPX's dividend (1.65%) is higher than the bottom 25% of dividend payers in the German market (1.47%).

High Dividend: HPX's dividend (1.65%) is low compared to the top 25% of dividend payers in the German market (3.83%).

Stable Dividend: HPX's dividends per share have been stable in the past 10 years.

Growing Dividend: HPX's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (39%), HPX's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Hisamitsu Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

JP¥177m

CEO Compensation


CEO

Hirotaka Nakatomi 0

0yrs

Tenure

JP¥177,000,000

Compensation

Mr. Hirotaka Nakatomi serves as the Chief Executive Officer of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi served as the President of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi serves as the Chairma ...


CEO Compensation Analysis

Compensation vs. Market: Hirotaka's total compensation ($USD1.63M) is about average for companies of similar size in the German market ($USD2.80M).

Compensation vs Earnings: Hirotaka's compensation has been consistent with company performance over the past year.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Hirotaka Nakatomi

    Chairman & CEO

    • Tenure: 0yrs
    • Compensation: JP¥177.00m
  • Kazuhide Nakatomi

    President & COO

    • Tenure: 0yrs
  • Mitsumasa Kabashima (69yo)

    President of Maruto Sangyo Co Ltd

    • Tenure: 9.4yrs
  • Tetsuo Akiyama

    Managing Director

    • Tenure: 0yrs
  • Kousuke Sugiyama

    Senior MD & GM of Human Resources

    • Tenure: 0yrs
  • Toshiaki Tsuruda (64yo)

    GM of Production Environment & Director

    • Tenure: 8.4yrs
  • Naruhito Higo

    Executive Officer & Director

    • Tenure: 7.8yrs
  • Shinichiro Takao

    GM of IR Department

    • Tenure: 0yrs
  • Kyu Saito

    Head of Corporate Strategy Planning Office & Director

    • Tenure: 0yrs

Board Members

  • Hirotaka Nakatomi

    Chairman & CEO

    • Tenure: 0yrs
    • Compensation: JP¥177.00m
  • Tetsuo Akiyama

    Managing Director

    • Tenure: 0yrs
  • Kousuke Sugiyama

    Senior MD & GM of Human Resources

    • Tenure: 0yrs
  • Isao Ichikawa

    Outside Director

    • Tenure: 0yrs
  • Toshiaki Tsuruda (64yo)

    GM of Production Environment & Director

    • Tenure: 8.4yrs
  • Naruhito Higo

    Executive Officer & Director

    • Tenure: 7.8yrs
  • Shinichiro Takao

    GM of IR Department

    • Tenure: 0yrs
  • Kyu Saito

    Head of Corporate Strategy Planning Office & Director

    • Tenure: 0yrs
  • Nobuo Tsutsumi

    Director

    • Tenure: 0yrs
  • Shinichi Murayama

    Director

    • Tenure: 0yrs

Company Information

Hisamitsu Pharmaceutical Co., Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hisamitsu Pharmaceutical Co., Inc.
  • Ticker: HPX
  • Exchange: DB
  • Founded: 1847
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥415.113b
  • Listing Market Cap: JP¥3.434b
  • Shares outstanding: 82.36m
  • Website: https://www.hisamitsu.co.jp

Number of Employees


Location

  • Hisamitsu Pharmaceutical Co., Inc.
  • 408, Tashiro Daikan-machi
  • Tosu
  • Saga
  • 841-0017
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4530TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
HPXDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
HTSU.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1992

Biography

Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals. The company offers SALONPAS pain relief products in the form of patches, spra ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 20:41
End of Day Share Price2019/10/18 00:00
Earnings2019/08/31
Annual Earnings2019/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.